We create novel small molecule immuno‑oncology therapeutics
Our compounds target components of the MMR pathway that have been validated in both clinical and preclinical studies. These components are known to modulate neoantigen creation and diversity across numerous cancers.Drugs that are designed to spark cancer neoantigen creation and subsequently stimulate the immune system can improve outcomes for patients who do not be...
We create novel small molecule immuno‑oncology therapeutics
Our compounds target components of the MMR pathway that have been validated in both clinical and preclinical studies. These components are known to modulate neoantigen creation and diversity across numerous cancers.Drugs that are designed to spark cancer neoantigen creation and subsequently stimulate the immune system can improve outcomes for patients who do not benefit from the current generation of cancer immunotherapies.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.